These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19487444)

  • 61. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.
    Zhanel GG; Sniezek G; Schweizer F; Zelenitsky S; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
    Drugs; 2009; 69(7):809-31. PubMed ID: 19441869
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).
    Mendes RE; Sader HS; Jones RN
    Int J Antimicrob Agents; 2010 Oct; 36(4):374-9. PubMed ID: 20598860
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Vinaxanthone, a new FabI inhibitor from Penicillium sp.
    Zheng CJ; Sohn MJ; Kim WG
    J Antimicrob Chemother; 2009 May; 63(5):949-53. PubMed ID: 19282328
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Linezolid resistance in coagulase-negative staphylococci.
    Kelly S; Collins J; Davin M; Gowing C; Murphy PG
    J Antimicrob Chemother; 2006 Oct; 58(4):898-9; author reply 899-900. PubMed ID: 16854956
    [No Abstract]   [Full Text] [Related]  

  • 65. In vitro activity of meropenem/piperacillin/tazobactam triple combination therapy against clinical isolates of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus pseudintermedius and vancomycin-resistant Enterococcus spp.
    Yoneda A; Thänert R; Burnham CD; Dantas G
    Int J Antimicrob Agents; 2020 Feb; 55(2):105864. PubMed ID: 31870598
    [TBL] [Abstract][Full Text] [Related]  

  • 66. In vitro activity of daptomycin and tigecycline against coagulase-negative staphylococcus blood isolates from bone marrow transplant recipients.
    Kratzer C; Rabitsch W; Hirschl AM; Graninger W; Presterl E
    Eur J Haematol; 2007 Nov; 79(5):405-9. PubMed ID: 17714506
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus.
    Fan F; Yan K; Wallis NG; Reed S; Moore TD; Rittenhouse SF; DeWolf WE; Huang J; McDevitt D; Miller WH; Seefeld MA; Newlander KA; Jakas DR; Head MS; Payne DJ
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3343-7. PubMed ID: 12384334
    [TBL] [Abstract][Full Text] [Related]  

  • 68. In vitro activity of novel rifamycins against gram-positive clinical isolates.
    Murphy CK; Karginova E; Sahm D; Rothstein DM
    J Antibiot (Tokyo); 2007 Sep; 60(9):572-6. PubMed ID: 17917240
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Phenylimidazole derivatives as specific inhibitors of bacterial enoyl-acyl carrier protein reductase FabK.
    Ozawa T; Kitagawa H; Yamamoto Y; Takahata S; Iida M; Osaki Y; Yamada K
    Bioorg Med Chem; 2007 Dec; 15(23):7325-36. PubMed ID: 17892940
    [TBL] [Abstract][Full Text] [Related]  

  • 70. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
    Pfaller MA; Farrell DJ; Sader HS; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).
    Fritsche TR; Sader HS; Stillwell MG; Jones RN
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):440-6. PubMed ID: 19302928
    [TBL] [Abstract][Full Text] [Related]  

  • 72. In-vitro activity of quinupristin/dalfopristin (Synercid) against isolates of Streptococcus pneumoniae, Staphylococcus aureus and enterococcus spp.
    Johnson AP; Warner M; Speller DC
    J Antimicrob Chemother; 1997 Oct; 40(4):604-5. PubMed ID: 9372437
    [No Abstract]   [Full Text] [Related]  

  • 73. In vitro activity of a new cephalosporin, RWJ-54428, against streptococci, enterococci and staphylococci, including glycopeptide-intermediate Staphylococcus aureus.
    Swenson JM; Tenover FC
    J Antimicrob Chemother; 2002 May; 49(5):845-50. PubMed ID: 12003982
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).
    Flamm RK; Mendes RE; Hogan PA; Streit JM; Ross JE; Jones RN
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2273-80. PubMed ID: 26833165
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
    Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2383-8. PubMed ID: 18443115
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI).
    Mehboob S; Song J; Hevener KE; Su PC; Boci T; Brubaker L; Truong L; Mistry T; Deng J; Cook JL; Santarsiero BD; Ghosh AK; Johnson ME
    Bioorg Med Chem Lett; 2015 Mar; 25(6):1292-6. PubMed ID: 25677657
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Ternary complex formation of AFN-1252 with Acinetobacter baumannii FabI and NADH: Crystallographic and biochemical studies.
    Rao NK; Nataraj V; Ravi M; Panchariya L; Palai K; Talapati SR; Lakshminarasimhan A; Ramachandra M; Antony T
    Chem Biol Drug Des; 2020 Aug; 96(2):704-713. PubMed ID: 32227402
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Postantibiotic and post-beta-lactamase inhibitor effects of amoxicillin plus clavulanate.
    Thorburn CE; Molesworth SJ; Sutherland R; Rittenhouse S
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2796-801. PubMed ID: 9124843
    [TBL] [Abstract][Full Text] [Related]  

  • 79. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
    Patel R; Rouse MS; Piper KE; Steckelberg JM
    Diagn Microbiol Infect Dis; 2000 Nov; 38(3):177-9. PubMed ID: 11109018
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Atromentin and leucomelone, the first inhibitors specific to enoyl-ACP reductase (FabK) of Streptococcus pneumoniae.
    Zheng CJ; Sohn MJ; Kim WG
    J Antibiot (Tokyo); 2006 Dec; 59(12):808-12. PubMed ID: 17323650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.